As per the agreement, Cellectis will receive $25M up front cash & $220M in equity investment incl. $80M in Cellectis common stock initially & $140M in Q1’24 at $5/share respectively
Cellectis is also eligible to receive an IND option fee & development, regulator & sales-based milestones for a value worth ~2.2B, an aggregate for 10 selected products, plus tiered royalties
AstraZeneca will develop ~10 new cell & gene therapies by leveraging Cellectis’ proprietary gene editing technologies & manufacturing capabilities. AstraZeneca was allocated a total of 25 genetic targets, of which around 10 can be probed further for potential development
Ref: AstraZeneca | Image: AstraZeneca
Related News:- LumiraDx Collaborates with AstraZeneca and Everton to Establish a Heart and Lung Screening Hub for its NT-proBNP Test Across England
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
